Clinical trial NCT03618368: Second Clinical Evaluation of THERANOVA-500 Dialyzer in Chronic Hemodialysis (HD)
Official title: Second Clinical Evaluation of THERANOVA-500 Dialyzer in Chronic Hemodialysis (HD)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: End Stage Renal Disease on Dialysis
Lead sponsor: Réseau de Santé Vitalité Health Network
Sponsor class: OTHER
First posted: 2018-08-07
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 1 blinded group on THERANOVA-500 dialyzer (Expanded Hemodialysis (HDx))

1 blinded group on REVACLEAR-400 dialyzer (conventional hemodialysis (HD))

1 non-blinded group on THERANOVA-500 dialyzer (Expanded Hemodialysis (HDx))

1 non-blinded group on REVACLEAR-400 dialyzer (conventional hemodialysis (HD))
Primary purpose: OTHER

Brief summary: Single blinded randomized controlled trial comparing Expanded Hemodialysis (HDx) using THERANOVA-500 dialyzer versus conventional hemodialysis (HD) using REVACLEAR-400 dialyzer in chronic hemodialysis patients over a 6-week intervention period. Primary endpoint is post-hemodialysis recovery time. Secondary endpoints are six pre-dialysis biomarker levels (b2-microglobuline, procalcitonine, free light chains (gamma-lambda), IL-6, CRP) and three Quality of Life (QoL)(adapted KDQoL-SF questionnaire, EQ-5D, and rESAS).

Detailed description: This is a randomized controlled trial involving 70 subjects divided in 4 groups: 25 single blinded subjects using THERANOVA-500 dialyzer enabling Expanded Hemodialysis (HDx) ; 25 single blinded subjects using REVACLEAR-400 dialyzer enabling conventional hemodialysis (HD); 10 non-blinded subjects using THERANOVA-500 enabling Expanded Hemodialysis (HDx) and 10 non-blinded subjects using REVACLEAR-400 dialyzer enabling conventional hemodialysis (HD) for their chronic hemodialysis treatments over an active intervention period of 6 weeks. All subjects are to be dialyzed using REVACLEAR-400 enabling conventional hemodialysis (HD) for two weeks prior and for two weeks after the intervention period.

Primary endpoint is mean post-hemodialysis recovery time (as reported by subjects once weekly) between groups (THERANOVA-500 vs REVACLEAR-400) (all subjects) during the 6-week intervention period.

Secondary endpoints are:

1. Post-hemodialysis recovery time change (mean of 2-week pre and 2-week post intervention period compared to mean during 6-week intervention period)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects),
2. Post-hemodialysis recovery time difference (mean between blinded and non-blinded THERANOVA-500 treated subjects during the 6-week intervention period,
3. Post-hemodialysis recovery time difference (mean between blinded and non-blinded REVACLEAR-400 treated subjects during the 6-week intervention period),
4. Post-hemodialysis recovery time difference mean gap between secondary endpoints 2 and 3,
5. Percentage of subjects who report no (zero) recovery time (mean THERANOVA-500 vs mean REVACLEAR-400) during 6-week intervention period (all subjects),
6. Pre and post 6-week intervention period pre-dialysis difference levels of beta-2 microglobulin (mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(in nmol/L),
7. Pre and post 6-week intervention period pre-dialysis difference levels of procalcitonin (mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(in ng/ml),
8. Pre and post 6-week intervention period pre-dialysis difference levels of free light chains (gamma and lambda)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(in mg/L),
9. Pre and post 6-week intervention period pre-dialysis difference levels of interleukine-6 (mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(in pg/ml),
10. Pre and post 6-week intervention period pre-dialysis difference levels of C reactive protein (CRP)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(in mg/L),
11. Quality of life change (pre and at 2 weeks of intervention period) (mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(assessed by adapted KDQoL-SF questionnaire)(max score 130),
12. Quality of life change (pre and at 4 weeks of intervention period) (mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects) assessed by adapted KDQoL-SF questionnaire)(max score 130),
13. Quality of life change (at 4 weeks of intervention period and week 8 of study)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects) assessed by adapted KDQoL-SF (max score 130),
14. Quality of life change (pre and at 2 weeks of intervention period)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(assessed by EQ-5D questionnaire)(max score 125),
15. Quality of life change (pre and at 4 weeks of intervention period)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(assessed by EQ-5D questionnaire)(max score 125),
16. Quality of life change (at 4 weeks of intervention period and week 8 of study)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(assessed by EQ-5D questionnaire (max score 125),
17. Quality of life change (pre and at 2 weeks of intervention period (mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(assessed by rESAS)(max score 100),
18. Quality of life change (pre and at 4 weeks of intervention period (mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(assessed by rESAS)(max score 100),
19. Quality of life change (at 4 weeks of intervention period and week 8 of study)(mean THERANOVA-500 vs mean REVACLEAR-400)(all subjects)(assessed by rESAS)(max score 100),
20. Subjects's QoL questionnaire fill preference (adapted KD QoL-SF vs EQ-5D vs rESAS) at study week 8.

Eligibility criteria: Inclusion Criteria:

* Age greater than 18 years, all genders.
* HD at DrGLDUHC for more than 3 months, 3 times/week schedule, and using REVACLEAR-400.
* Good vascular access (blood flow (Qb) \> 300 during entire previous 6 HD sessions, no per-HD alteplase treatments used over the last 2 weeks, routine alteplase-lock allowed)
* Signed informed consent
* Likely to be able to participate for the duration of the clinical evaluation (no trips, no elective procedures, no transfer to another dialysis modality or HD facility, etc).
* Able to fill questionnaires, staff assistance allowed.

Exclusion Criteria:

* HD more than 3 times/week
* HD on other dialyzers than REVACLEAR-400
* Poor vascular access (from staff and Nephrologists' evaluation)
* No consent or unable to answer questionnaires even with staff assistance.

Primary outcomes:
measure: Post-dialysis recovery time (intervention period)
timeFrame: through 6-week intervention period
Secondary outcomes:
measure: Post-hemodialysis recovery time change (THERANOVA-500 vs REVACLEAR-400)
timeFrame: through 10-week study
measure: Post-hemodialysis recovery time difference (THERANOVA-500)
timeFrame: through 6-week intervention period
measure: Post-hemodialysis recovery time difference (REVACLEAR-400)
timeFrame: through 6-week intervention period
measure: Post-hemodialysis recovery time difference mean gap (THERANOVA-500 vs REVACLEAR-400)
timeFrame: through 6-week intervention period
measure: Percentage of subjects who report no (zero) recovery time (THERANOVA-500 vs REVACLEAR-400)
timeFrame: through 6-week intervention period
measure: Pre and post 6-week intervention period pre-dialysis levels of beta-2 microglobulin
timeFrame: 6 weeks
measure: Pre and post 6-week intervention period pre-dialysis levels of procalcitonin
timeFrame: 6 weeks
measure: Pre and post 6-week intervention period pre-dialysis levels of free light chains
timeFrame: 6 weeks
measure: Pre and post 6-week intervention period pre-dialysis levels of interleukine-6
timeFrame: 6 weeks
measure: Pre and post 6-week intervention period pre-dialysis levels of C reactive protein
timeFrame: 6 weeks
measure: Quality of life (QoL) change (pre and at 2 weeks of intervention period)(adapted KDQoL-SF)
timeFrame: 2 weeks
measure: Quality of life (QoL) change (pre and at 4 weeks of intervention period)(adapted KDQoL-SF)
timeFrame: 4 weeks
measure: Quality of life (QoL) change (at 4 weeks of intervention period and week 8 of study)(adapted KDQoL-SF)
timeFrame: 4 weeks
measure: Quality of life (QoL) change (pre and at 2 weeks of intervention period)(EQ-5D)
timeFrame: 2 weeks
measure: Quality of life (QoL) change (pre and at 4 weeks of intervention period)(EQ-5D)
timeFrame: 4 weeks
measure: Quality of life (QoL) change (at 4 weeks of intervention period and week 8 of study)(EQ-5D)
timeFrame: 4 weeks
measure: Quality of life (QoL) change (pre and at 2 weeks of intervention period)(rESAS)
timeFrame: 2 weeks
measure: Quality of life (QoL) change (pre and at 4 weeks of intervention period)(rESAS)
timeFrame: 4 weeks
measure: Quality of life (QoL) change (at 4 weeks of intervention period and week 8 of study)(rESAS)
timeFrame: 4 weeks
measure: Subjects's QoL questionnaire fill preference
timeFrame: at week 10 of study
Other outcomes:
Locations:
city: Moncton
country: Canada
facility: Dr Georges-L.-Dumont University Hospital Centre
state: New Brunswick
Study officials:
affiliation: Dr Georges-L.-Dumont University Hospital Centre
name: Marc Dorval, MD,MPH,MBA
role: PRINCIPAL_INVESTIGATOR
References: